Observational studyFrontiers in immunology2024

Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China.

Yuyi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.